CD19+ Malignant Leukemia and Lymphoma
Conditions
Interventions
Case series:N/A
Sponsors
Renji Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Subjects with documented CD19-positive malignant B cell leukemia and lymphoma. 1. Patients aged between 18 ~ 65 with malignant B cell leukemia and lymphoma; 2. CD19-positive B cell leukemia or lymphoma; 3. Expected survival > 12 weeks; 4. ECOG scores 0-1, or KPS scores > 80; 5. Adequate venous access for apheresis or venous sampling, and no other contraindications for leukapheresis. 6. WBC = 2.5×10^9/L; LY = 0.7×109/L; LY% = 15%; 7. Creatinine = 2.0 mg/dL (176.8 µmol/L); 8. ALT/AST = 2.5 ULN; 9. Bilirubin = 2.0 mg/dL (34.2 µmol/L); 10. Prothrombin Time (PT): International Normalized Ratio (INR) < 1.7, or PT is at most 4 s longer than normal value. All tests results should comply with the above criteria. No continuing supportive care is received.
Exclusion criteria
Exclusion criteria: 1. CD19-negative B cell leukemia or lymphoma; 2. Feasibility assessment during screening demonstrates 300 mg/d; Clopidogrel, dose > 75 mg/d); 17. Any radiotherapy conducted within 4 weeks prior to blood sampling.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cytokinetics;Safety & tolerance; | — |
Countries
China
Contacts
Public ContactFangyuan Chen
Renji Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed